Mechanism of resistance to bet bromodomain inhibitors
AssigneeDana-Farber Cancer Institute, Inc.
InventorsKornelia Polyak, Shaokun Shu, James E. Bradner, Charles Yang Lin
Life of this patent
Estimating the term…
Abstract
The present disclosure provides combination therapy comprising a BET inhibitor and a protein phosphatase 2A (PP2A) activator, a B-cell lymphoma-2 (Bcl-2) inhibitor, a B-cell lymphoma-extra large (Bcl-xl) inhibitor, a casein kinase 2 (CK2) inhibitor, and/or a mediator complex subunit 1 (MED1) for cancer. The combination therapy is expected to be synergistic in treating the cancer, compared to the monotherapy. Methods for identifying a subject having a cancer that is resistant to or at risk of developing resistance to bromodomain and extra terminal (BET) inhibitor therapy are also provided.
Claims26
A method for treating a cancer, the method comprising:
- administering to a subject in need thereof a bromodomain and extra terminal (BET) inhibitor and a protein phosphatase 2A (PP2A) activator in an amount effective to treat the cancer.
A method for treating cancer, the method comprising:
- administering to a subject in need thereof a bromodomain and extra terminal (BET) inhibitor and a B-cell lymphoma-extra large (Bcl-xl) inhibitor in an amount effective to treat the cancer.
13-21 (canceled)
A method for treating cancer, the method comprising:
- administering to a subject in need thereof a bromodomain and extra terminal (BET) inhibitor and a casein kinase 2 (CK2) inhibitor in an amount effective to treat the cancer.
23-31 (canceled)
A method for treating cancer, the method comprising:
- administering to a subject in need thereof a bromodomain and extra terminal (BET) inhibitor and a mediator complex subunit 1 (MED1) inhibitor in an amount effective to treat the cancer.
33-41 (canceled)
A method to identify a subject having a cancer that is resistant to or at risk of developing resistance to bromodomain and extra terminal (BET) inhibitor therapy, the method comprising:
- performing an assay to determine intracellular location of bromodomain-containing protein 4 (BRD4) in a tumor sample obtained from a subject receiving BET inhibitor therapy;
- and
- identifying the subject as having a cancer that is resistant to or at risk of developing resistance to BET inhibitor therapy if the BRD4 has a nuclear localization.
43-46 (canceled)
A method to identify a subject having a cancer that is resistant to or at risk of developing resistance to bromodomain and extra terminal (BET) inhibitor therapy, the method comprising:
- performing an assay to determine a ratio of phosphorylated bromodomain-containing protein 4 (pBRD4) to un-phosphorylated BRD4 (BRD4) in a tumor sample obtained from a subject having a cancer;
- and
- identifying the subject as having a cancer that is resistant to or at risk of developing resistance to BET inhibitor therapy if the ratio of pBRD4 to BRD4 is increased as compared to a control ratio of pBRD4 to BRD4.
48-51 (canceled)
A method for treating cancer, the method comprising:
- administering to a subject in need thereof a bromodomain and extra terminal (BET) inhibitor and a B-cell lymphoma-2 (Bcl-2) inhibitor in an amount effective to treat the cancer.
53-61 (canceled)
Dependencies are inferred from the claim text.